Abstract:Objective: Obesity alters sex hormone balance in males, resulting in low testosterone and altered metabolism of estrogen, independent risk factors for cardiometabolic dysfunction. The basis of these alterations and how they are impacted by factors that improve cardiometabolic outcomes in obesity are unknown. Methods: Control and obese mice ( db/db) with or without deletion of myostatin to induce hypermuscularity were used. Mice were analyzed for plasma sex hormones via mass-spectrometry with or without 10mg/kg/day fadrazole to inhibit aromatase. Quantitative PCR was used to measure aromatase along with cytochrome P450 enzymes involved in estrogen metabolism in the liver, skeletal muscle, and visceral adipose tissue. HEK293a cells were treated with myostatin in vitro and enzyme levels assessed. Results: Obesity decreased plasma testosterone 30% and increased estrogen 20% with no change in gonadal weight. Deletion of myostatin increased muscle mass >30% and resulted in a reduction in estrogen levels without a parallel increase in androgens in obese mice. Inhibition of aromatase restores estrogen levels indicating the excess estrogen in obesity is derived from testosterone conversion. Since estrogen was lowered without increasing testosterone and estrogen metabolism must be increased. Aromatase was increased in obesity but unaffected by changes in muscle mass. CYP1B1, an enzyme that converts estradiol to hydroxy estrogens, showed 2.5 fold expression in obese skeletal muscle, which is improved in the absence of myostatin, with no change in other P450s involved in estrogen metabolism. Moreover, changes in P450 enzymes in liver or fat were either absent or changed directionally opposite to observed hormone changes. In HEK cells, treatment with myostatin recapitulated changes in CYP1B1 expression seen in vitro, suggesting a direct link between the myokine and sex hormone metabolism by skeletal muscle. Conclusion: In summary, obesity causes a shift in sex hormone levels to estrogen production, which is improved by myostatin deletion, without restoration of androgens. A potential mechanism responsible could be altered estrogen catabolism, leading to decreased estrogen levels without the restoration of androgen levels. Together, these data suggest CYP1B1 drives the conversion of estrogen to hydroxestrogens, which are known pro-oxidant and pro-lipidemic influences that may contribute to cardiometabolic disease. Whether targeting CYP1B1 improves cardiometabolic function in obesity remains to be determined. D.W. Stepp and D.J. Fulton are supported by NIH 1R01HL147159 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Deletion of myostatin alters obesity-induced estrogen metabolism in skeletal muscle